San Diego, CA, United States of America

Raymond Dagnino, Jr


Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 26(Granted Patents)


Location History:

  • El Cajon, CA (US) (2002 - 2004)
  • San Diego, CA (US) (1996 - 2005)

Company Filing History:


Years Active: 1996-2005

Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Raymond Dagnino, Jr.

Introduction

Raymond Dagnino, Jr. is a notable inventor based in San Diego, California, recognized for his significant contributions to the field of pharmaceuticals. With a total of seven patents to his name, Dagnino has made strides in developing compounds that target various medical conditions.

Latest Patents

Dagnino's latest patents include innovations related to metalloproteinase inhibitors and efficient synthetic routes for rhinovirus protease inhibitors. His work on metalloproteinase inhibitors involves pharmaceutical compositions that contain these compounds and their uses in treating diseases. The invention details compounds with specific structural formulas, including prodrugs, salts, and solvates. Additionally, his research on rhinovirus protease inhibitors focuses on efficient synthetic routes and key intermediates that are essential for treating infections caused by picornaviruses.

Career Highlights

Throughout his career, Dagnino has worked with prominent companies in the pharmaceutical industry, including Agouron Pharmaceuticals, Inc. and Corvas International, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Dagnino has collaborated with notable professionals in his field, including Steven Lee Bender and Michael J. Melnick. These collaborations have likely enhanced his research and development efforts, leading to impactful inventions.

Conclusion

Raymond Dagnino, Jr. exemplifies the spirit of innovation in the pharmaceutical industry through his patents and collaborations. His work continues to influence the development of new therapeutic compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…